Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | DGKA | P23743 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16380604 | 0.85 | NAAA (0.68) | NAAAMAPTSMN1; SMN2LMNATSHR | |
| SCHEMBL15028306 | 0.85 | NAAA (0.68) | NAAAMAPTSMN1; SMN2LMNATSHR | |
| SCHEMBL4978268 | 0.84 | NAAA (0.82) | NAAASMN1; SMN2LMNADGKAPRKCA | |
| SCHEMBL16380613 | 0.84 | NAAA (0.69) | NAAASMN1; SMN2LMNATSHRMETAP1 | |
| SCHEMBL16380552 | 0.84 | NAAA (0.69) | NAAASMN1; SMN2LMNATSHRMETAP1 | |
| SCHEMBL15268267 | 0.83 | NAAA (0.49) | NAAAMAPTSMN1; SMN2LMNATSHR | |
| SCHEMBL30915389 | 0.83 | NAAA (0.86) | NAAAMAPTSMN1; SMN2LMNADGKA | |
| SCHEMBL28454438 | 0.83 | NAAA (0.86) | NAAAMAPTSMN1; SMN2LMNADGKA | |
| SCHEMBL16046795 | 0.83 | NAAA (0.86) | NAAAMAPTSMN1; SMN2LMNADGKA | |
| SCHEMBL27913647 | 0.83 | NAAA (0.86) | NAAAMAPTSMN1; SMN2LMNADGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517909-B2 | Amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY S | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, SCN1A | NAAA 1406/4885MAPT 646/4885SMN1; SMN2 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.